Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · IEX Real-Time Price · USD
43.10
-0.70 (-1.60%)
At close: Jul 19, 2024, 4:00 PM
42.72
-0.38 (-0.88%)
Pre-market: Jul 22, 2024, 7:44 AM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $79.41M in the twelve months ending March 31, 2024, with 70.16% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $10.29M with 8.67% year-over-year growth. In the year 2023, Kymera Therapeutics had annual revenue of $78.59M with 67.84% growth.
Revenue (ttm)
$79.41M
Revenue Growth
+70.16%
P/S Ratio
33.30
Revenue / Employee
$424,668
Employees
187
Market Cap
2.64B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
Dec 31, 2019 | 2.93M | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.97B |
Ardent Health Partners | 5.53B |
Integra LifeSciences Holdings | 1.53B |
Astrana Health | 1.45B |
Progyny | 1.11B |
PTC Therapeutics | 927.56M |
Certara | 360.69M |
Agios Pharmaceuticals | 29.40M |
KYMR News
- 12 days ago - Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug - Investopedia
- 13 days ago - Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day - GlobeNewsWire
- 13 days ago - Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy - GlobeNewsWire
- 5 weeks ago - Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting - GlobeNewsWire
- 7 weeks ago - Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - GlobeNewsWire
- 7 weeks ago - Kymera Therapeutics to Participate in Upcoming June Investor Conferences - GlobeNewsWire
- 2 months ago - Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting - GlobeNewsWire